PERSONENI, Nicola
PERSONENI, Nicola
Dipartimento Scienze Biomediche
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma
2013-01-01 Rimassa, L; Pressiani, T; Boni, C; Carnaghi, C; Rota Caremoli, E; Fagiuoli, S; Foa, P; Salvagni, S; Cortesi, E; Tronconi, Mc; Personeni, N; Bozzarelli, S; Banzi, Mc; Fanello, S; Lutman, Fr; Giordano, L; Santoro, A
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
2015-01-01 Santoro, A; Gebbia, V; Pressiani, T; Testa, A; Personeni, N; Bajardi, Ea; Foa, P; Buonadonna, A; Bencardino, K; Barone, C; Ferrari, D; Zaniboni, A; Tronconi, Mc; Carteni, G; Milella, M; Comandone, A; Ferrari, S; Rimassa, L
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer
2007-01-01 M, Colozza; E, Azambuja; Personeni, N.; F, Lebrun; Mj, Piccart; F., Cardoso
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
2010-01-01 Santoro, A; Pressiani, T; Citterio, G; Rossoni, G; Donadoni, G; Pozzi, F; Rimassa, L; Personeni, N; Bozzarelli, S; Rossoni, G; Colombi, S; De Braud, Fg; Caligaris-Cappio, F; Lambiase, A; Bordignon, C
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough?
2011-01-01 Personeni, N.; Torzilli, G.; Santoro, A.
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases
2018-01-01 Vigano, L; Pedicini, V; Comito, T; Carnaghi, C; Costa, G; Poretti, D; Franzese, C; Personeni, N; Del Fabbro, D; Rimassa, L; Scorsetti, M; Santoro, A; Solbiati, L; Torzilli, G
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner
2020-01-01 Campani, Claudia; Rimassa, Lorenza; Personeni, Nicola; Marra, Fabio
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
2021-01-01 Jun, Tomi; Ozbek, Umut; Dharmapuri, Sirish; Hardy-Abeloos, Camille; Zhu, Huili; Lin, Jung-Yi; Personeni, Nicola; Pressiani, Tiziana; Nishida, Naoshi; Lee, Pei-Chang; Lee, Chieh-Ju; Hildebrand, Hannah; Nimkar, Neil; Paul, Sonal; Fessas, Petros; Naeem, Muntaha; Bettinger, Dominik; Khan, Uqba; Saeed, Anwaar; Huang, Yi-Hsiang; Kudo, Masatoshi; Rimassa, Lorenza; Marron, Thomas U; Pinato, David J; Ang, Celina
Are we ready for patient-reported outcomes in hepatocellular carcinoma?
2021-01-01 Personeni, Nicola; Rimassa, Lorenza
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA)
2016-01-01 Mazzaferro, V. M.; Shaib, W.; Rimassa, L.; Harris, W.; Personeni, N.; El-rayes, B.; Tolcher, A.; Hall, T.; Wang, Y.; Schwartz, B.; Kazakin, J.; Michele, DROZ DIT BUSSET; Cotsoglou, C.; Papadopoulos, K.
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights
2022-01-01 Cammarota, Antonella; Zanuso, Valentina; Pressiani, Tiziana; Personeni, Nicola; Rimassa, Lorenza
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications
2016-01-01 Personeni, N; Baretti, M; Bozzarelli, S; Spaggiari, P; Rubino, L; Tronconi, Mc; Fumagalli, U; Rosati, R; Giordano, L; Roncalli, M; Santoro, A; Rimassa, L
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
2021-01-01 D'Alessio, Antonio; Cammarota, Antonella; Zanuso, Valentina; Pressiani, Tiziana; Personeni, Nicola; Rimassa, Lorenza
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
2020-01-01 Personeni, Nicola; Lleo, Ana; Pressiani, Tiziana; Colapietro, Francesca; Openshaw, Mark Robert; Stavraka, Chara; Pouptsis, Athanasios; Pinato, David James; Rimassa, Lorenza
Biomarkers in Hepatocellular Carcinoma-Letter
2012-01-01 Personeni, N; Rimassa, L; Santoro, A
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer
2019-01-01 Mennini, Fs; Marcellusi, A; Fabiano, G; Rimassa, L; Santoro, A; Personeni, N
Cabozantinib for the treatment of hepatocellular carcinoma
2019-01-01 Personeni, N; Rimassa, L; Pressiani, T; Smiroldo, V; Santoro, A
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib
2019-01-01 Personeni, N; Pressiani, T; Rimassa, L
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials
2022-01-01 Cammarota, Antonella; Zanuso, Valentina; D'Alessio, Antonio; Pressiani, Tiziana; Personeni, Nicola; Rimassa, Lorenza
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study
2016-01-01 Comito, T; Cozzi, L; Clerici, E; Franzese, C; Tozzi, A; Iftode, C; Navarria, P; D’Agostino, G; Rimassa, L; Carnaghi, C; Personeni, N; Tronconi, Mc; De Rose, F; Franceschini, D; Ascolese, Am; Fogliata, A; Tomatis, S; Santoro, A; Zerbi, A; Scorsetti, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma | 1-gen-2013 | Rimassa, L; Pressiani, T; Boni, C; Carnaghi, C; Rota Caremoli, E; Fagiuoli, S; Foa, P; Salvagni, S; Cortesi, E; Tronconi, Mc; Personeni, N; Bozzarelli, S; Banzi, Mc; Fanello, S; Lutman, Fr; Giordano, L; Santoro, A | |
| A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study | 1-gen-2015 | Santoro, A; Gebbia, V; Pressiani, T; Testa, A; Personeni, N; Bajardi, Ea; Foa, P; Buonadonna, A; Bencardino, K; Barone, C; Ferrari, D; Zaniboni, A; Tronconi, Mc; Carteni, G; Milella, M; Comandone, A; Ferrari, S; Rimassa, L | |
| Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer | 1-gen-2007 | M, Colozza; E, Azambuja; Personeni, N.; F, Lebrun; Mj, Piccart; F., Cardoso | |
| Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma | 1-gen-2010 | Santoro, A; Pressiani, T; Citterio, G; Rossoni, G; Donadoni, G; Pozzi, F; Rimassa, L; Personeni, N; Bozzarelli, S; Rossoni, G; Colombi, S; De Braud, Fg; Caligaris-Cappio, F; Lambiase, A; Bordignon, C | |
| Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? | 1-gen-2011 | Personeni, N.; Torzilli, G.; Santoro, A. | |
| Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases | 1-gen-2018 | Vigano, L; Pedicini, V; Comito, T; Carnaghi, C; Costa, G; Poretti, D; Franzese, C; Personeni, N; Del Fabbro, D; Rimassa, L; Scorsetti, M; Santoro, A; Solbiati, L; Torzilli, G | |
| Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner | 1-gen-2020 | Campani, Claudia; Rimassa, Lorenza; Personeni, Nicola; Marra, Fabio | |
| Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma | 1-gen-2021 | Jun, Tomi; Ozbek, Umut; Dharmapuri, Sirish; Hardy-Abeloos, Camille; Zhu, Huili; Lin, Jung-Yi; Personeni, Nicola; Pressiani, Tiziana; Nishida, Naoshi; Lee, Pei-Chang; Lee, Chieh-Ju; Hildebrand, Hannah; Nimkar, Neil; Paul, Sonal; Fessas, Petros; Naeem, Muntaha; Bettinger, Dominik; Khan, Uqba; Saeed, Anwaar; Huang, Yi-Hsiang; Kudo, Masatoshi; Rimassa, Lorenza; Marron, Thomas U; Pinato, David J; Ang, Celina | |
| Are we ready for patient-reported outcomes in hepatocellular carcinoma? | 1-gen-2021 | Personeni, Nicola; Rimassa, Lorenza | |
| ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) | 1-gen-2016 | Mazzaferro, V. M.; Shaib, W.; Rimassa, L.; Harris, W.; Personeni, N.; El-rayes, B.; Tolcher, A.; Hall, T.; Wang, Y.; Schwartz, B.; Kazakin, J.; Michele, DROZ DIT BUSSET; Cotsoglou, C.; Papadopoulos, K. | |
| Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights | 1-gen-2022 | Cammarota, Antonella; Zanuso, Valentina; Pressiani, Tiziana; Personeni, Nicola; Rimassa, Lorenza | |
| Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications | 1-gen-2016 | Personeni, N; Baretti, M; Bozzarelli, S; Spaggiari, P; Rubino, L; Tronconi, Mc; Fumagalli, U; Rosati, R; Giordano, L; Roncalli, M; Santoro, A; Rimassa, L | |
| Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma | 1-gen-2021 | D'Alessio, Antonio; Cammarota, Antonella; Zanuso, Valentina; Pressiani, Tiziana; Personeni, Nicola; Rimassa, Lorenza | |
| Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options | 1-gen-2020 | Personeni, Nicola; Lleo, Ana; Pressiani, Tiziana; Colapietro, Francesca; Openshaw, Mark Robert; Stavraka, Chara; Pouptsis, Athanasios; Pinato, David James; Rimassa, Lorenza | |
| Biomarkers in Hepatocellular Carcinoma-Letter | 1-gen-2012 | Personeni, N; Rimassa, L; Santoro, A | |
| Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer | 1-gen-2019 | Mennini, Fs; Marcellusi, A; Fabiano, G; Rimassa, L; Santoro, A; Personeni, N | |
| Cabozantinib for the treatment of hepatocellular carcinoma | 1-gen-2019 | Personeni, N; Rimassa, L; Pressiani, T; Smiroldo, V; Santoro, A | |
| Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib | 1-gen-2019 | Personeni, N; Pressiani, T; Rimassa, L | |
| Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials | 1-gen-2022 | Cammarota, Antonella; Zanuso, Valentina; D'Alessio, Antonio; Pressiani, Tiziana; Personeni, Nicola; Rimassa, Lorenza | |
| Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study | 1-gen-2016 | Comito, T; Cozzi, L; Clerici, E; Franzese, C; Tozzi, A; Iftode, C; Navarria, P; D’Agostino, G; Rimassa, L; Carnaghi, C; Personeni, N; Tronconi, Mc; De Rose, F; Franceschini, D; Ascolese, Am; Fogliata, A; Tomatis, S; Santoro, A; Zerbi, A; Scorsetti, M |